We would like to share ideas on the publication “Worsening of immune thrombocytopenic purpura (ITP) in SARS-CoV-2 vaccinated patients.1” Garca Ramrez et al. provided an interesting case report and proposed that a platelet count should be collected before and after vaccination in persons with pre-existing ITP to avoid deadly bleeding episodes.1 We’ve encountered some ITP patients in our clinic who were given COVID-19 and had no side effects. However, in our scenario, the COVID-19 vaccine that is administered locally is the non-mRNA COVID-19 vaccine. The specific association between COVID-19 vaccine and clinical course ITP COVID-19 vaccine recipient with underlying ITP is frequently difficult to determine. The cases reported by Garca Ramrez et al. definitely indicated a decrease in platelet count, but there is no information on immunological parameters or a search for other possible causes of thrombocytopenia. Dengue fever has been recorded as a concurrent medical concern in a COVID-19 vaccine recipient in our tropical setting, causing thrombocytopenia.2 This emphasizes the importance of a thorough clinical study before concluding that thrombocytopenia in a COVID-19 vaccine recipient is an unfavorable consequence of the vaccine.
FundingNo funding.
